These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35487700)

  • 21. Regional glucose metabolism due to the presence of cerebral amyloidopathy in older adults with depression and mild cognitive impairment.
    Youn H; Lee ES; Lee S; Suh S; Jeong HG; Eo JS
    J Affect Disord; 2018 Oct; 239():30-36. PubMed ID: 29991443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration patterns of brain glucose metabolism: comparisons of healthy controls, subjective memory impairment and mild cognitive impairment.
    Song IU; Choi EK; Oh JK; Chung YA; Chung SW
    Acta Radiol; 2016 Jan; 57(1):90-7. PubMed ID: 25538106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism.
    Smailovic U; Koenig T; Savitcheva I; Chiotis K; Nordberg A; Blennow K; Winblad B; Jelic V
    Brain Connect; 2020 Dec; 10(10):555-565. PubMed ID: 33073602
    [No Abstract]   [Full Text] [Related]  

  • 24. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging.
    Krell-Roesch J; Syrjanen JA; Vassilaki M; Lowe VJ; Vemuri P; Mielke MM; Machulda MM; Stokin GB; Christianson TJ; Kremers WK; Jack CR; Knopman DS; Petersen RC; Geda YE
    Am J Geriatr Psychiatry; 2021 Feb; 29(2):179-191. PubMed ID: 32646634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI.
    Caminiti SP; De Francesco S; Tondo G; Galli A; Redolfi A; Perani D; ;
    Alzheimers Dement; 2024 Jan; 20(1):159-172. PubMed ID: 37505996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
    Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
    Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.
    Caselli RJ; Chen K; Lee W; Alexander GE; Reiman EM
    Arch Neurol; 2008 Sep; 65(9):1231-6. PubMed ID: 18779428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population.
    Dong QY; Li TR; Jiang XY; Wang XN; Han Y; Jiang JH
    Alzheimers Res Ther; 2021 Apr; 13(1):74. PubMed ID: 33827675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups.
    Groot C; Risacher SL; Chen JQA; Dicks E; Saykin AJ; Mac Donald CL; Mez J; Trittschuh EH; Mukherjee S; Barkhof F; Scheltens P; van der Flier WM; Ossenkoppele R; Crane PK;
    Neuroimage Clin; 2021; 31():102725. PubMed ID: 34153688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
    Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena.
    Ashraf-Ganjouei A; Moradi K; Faghani S; Abdolalizadeh A; Khomeijani-Farahani M; Fatehi F; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2021; 18(9):721-731. PubMed ID: 34819007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
    Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
    Landau SM; Mintun MA; Joshi AD; Koeppe RA; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
    Ann Neurol; 2012 Oct; 72(4):578-86. PubMed ID: 23109153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.